NCT00293215View on ClinicalTrials.gov

Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Neoplasms
Interventions
DRUG

111-Indium-CMD-193

111-In-CMD-193 (3-7 mCi) was administered as an IV infusion over 60 (± 5) minutes.

DRUG

CMD-193

CMD-193 was administered as an IV infusion over 60 (± 5) minutes.

Trial Locations (2)

3084

Ludwig Institute Tumor Targeting Program, Austin Health, Heidelberg (Melbourne)

4209

Cancer Care Services, Dept. of Medical Oncology, Royal Brisbane and Women's Hospital, Herston

Sponsors
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Ludwig Institute for Cancer Research

OTHER